key: cord-0786675-bqnadvly
authors: Godon, Alexandre; Durand, Zoé; Agier, Lydiane; Lecompte, Thomas; Mullier, François; Marlu, Raphaël; de Maistre, Emmanuel; Tacquard, Charles; Levy, Jerrold H.; Godier, Anne; Susen, Sophie; Albaladejo, Pierre
title: Comparison of Fibrin Monomers and D-dimers to predict thrombotic events in critically ill patients with COVID-19 pneumonia: a retrospective study
date: 2021-06-19
journal: Thromb Res
DOI: 10.1016/j.thromres.2021.06.009
sha: 7ad129f4f4274c0447c3b3fe11d3761712f532c4
doc_id: 786675
cord_uid: bqnadvly

nan

Coronavirus disease 2019 (COVID-19) is associated with a high risk of thrombotic events, particularly in critically ill patients. Anticoagulants at higher than standard thromboprophylaxis doses have been advocated by our group [1] . Although higher doses may help reduce thrombotic complications, the risk of hemorrhage could limit the benefit of such a strategy unless individualized to high thrombotic risk patients. D-dimers have been extensively studied in COVID-19, and elevated levels are associated with increased mortality, but whether it predicts thrombotic events is unclear. Another fibrin-related biomarker is Fibrin Monomers (FM), which seems promising to detect hypercoagulable state earlier than other coagulation biomarkers [2] . To investigate if FM can predict thrombotic events in critically ill COVID-19 patients, we conducted a subanalysis of the COVICLOT study [3] and evaluated all patients with at least one FM measurement. The protocol was approved by the University Hospital of Strasbourg Ethics Committee (reference CE-2020-76).

All consecutive patients with RT-PCR-confirmed COVID-19 who were hospitalized in an intensive care unit (ICU) for severe hypoxemia were included. Baseline characteristics were collected at admission (Day 0), and patients were managed according to the standard of care. Differences between two consecutive FM or peak value measurements were not associated with thrombotic events. ROC analysis showed that the FM level at day 2 was comparable to the D-dimer assay to predict thrombotic events (Figure 2 ). The optimal cutoff value was determined at 5700 µg/L for FM to predict thrombotic events, with a sensitivity of 67% (95% CI 39-86) and a specificity of 77% (95% CI 61-88). Optimal cutoff for D-dimers was 3300 µg/L with a sensitivity of 75% (95%CI 47-91) and a specificity of 71% (95% CI 55-84).

Diagnostic performance was comparable when considering only pulmonary embolism, or when excluding catheter, dialysis filter and ECMO-related thromboses.

FM levels reflect thrombin activity and seem promising to predict thrombotic events, despite minimal evidence to implement them into clinical practice [2] . In non-COVID surgical patients, high soluble FM on postoperative day 1 is associated with a hypercoagulable state [6] , and was found to be more sensitive than D-dimers and other fibrin-related markers to predict thrombotic events [7] . In COVID-19 patients, high D-dimers levels are associated with the extent of lung injury and could reflect extravascular fibrin deposits [8] . On the contrary, soluble FM is theoretically limited to the intravascular space. We found that FM plasma level distributions over time differ from D-dimers, with most FM levels being under the limit of detection, although we did not find an increased diagnostic performance of FM over D-dimers to predict thrombotic events. These findings are in line with other studies.

Sridharan et al. found that FM levels were elevated in only 18.5% of COVID-19 patients with elevated D-dimers [9] . Hardy et al. reported in critically ill COVID-19 patients that the majority of FM levels were within the manufacturer's range, in sharp contrast with D-dimers [10] . As stated by the authors, this could be advantageous to capture an abrupt rise in FM levels. Whether FM alone or in combination with D-dimers could be more useful than Ddimers alone to individualize anticoagulation management remains to be determined. This study has several limitations: it is a retrospective study, with a relatively small sample size. Patients rarely had FM measurements at all time points, and 68 (41%) had only one measurement over the study period. Data were collected every three days, whereas FM have a short half-life (2.3 hours) with transient peaks [8, 10] . We may therefore lack the statistical power to demonstrate a clear usefulness of FM over D-dimers. Although FM levels are increased in patients with disseminated intravascular coagulation, cancer, and pregnancy [2] , few patients in our study had these conditions.

In conclusion, FM plasma levels were often under the limit of detection in critically ill COVID-19 patients and showed no clear superiority over D-dimers to predict thrombotic events. Prospective studies with closer monitoring of this hemostatic biomarker are needed to determine its usefulness to stratify thrombotic risk and individualize anticoagulation management. 

Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring

The Clinical Significance of Fibrin Monomers

Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia

Anticoagulation in COVID-19: not strong for too long?

Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study

Associations between venous thromboembolism onset, D-dimer, and soluble fibrin monomer complex after total knee arthroplasty

The value of quantitative fibrin monomer determination in the early diagnosis of postoperative deep vein thrombosis

D-Dimers Level as a Possible Marker of Extravascular Fibrinolysis in COVID-19 Patients

Evaluation of Soluble Fibrin Monomer Complex in Patients with Sars-Cov-2 COVID-19 Infection

Could Daily Monitoring of Fibrin Related Markers Help Suspect a Thrombotic Event in COVID-19 Patients? A Prospective Pilot Study

Funding: this research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: